திறந்த ஆர்ஃபந் பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

7:09 am
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has announced that drug development company PrEP Biopharm Limited, which is 62.6% owned by Open Orphan, has successfully completed a 12-week toxicology study for its novel pan-viral prophylactic asset, PrEP-001.
The animal model study provides safety data needed to move PrEP-001 into longer duration dosing in clinical studies. PrEP Biopharm intends to move forward with a real-world, field trial intended to validate the efficacy of its PrEP-001 against all circulating respiratory viruses, including COVID-19, influenza and the common cold. ....

Cathal Friel , Venn Life Sciences , Prep Biopharm , Open Orphan , Open Orphan Board , Executive Chairman , வென் வாழ்க்கை அறிவியல் , ப்ரெப் பிோபர்ம் , திறந்த ஆர்ஃபந் , திறந்த ஆர்ஃபந் பலகை , நிர்வாகி தலைவர் ,